Cargando…

Thioglycosides Act as Metabolic Inhibitors of Bacterial Glycan Biosynthesis

[Image: see text] Glycans that coat the surface of bacteria are compelling antibiotic targets because they contain distinct monosaccharides that are linked to pathogenesis and are absent in human cells. Disrupting glycan biosynthesis presents a path to inhibiting the ability of a bacterium to infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Quintana, Isabella de la Luz, Paul, Ankita, Chowdhury, Aniqa, Moulton, Karen D., Kulkarni, Suvarn S., Dube, Danielle H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580310/
https://www.ncbi.nlm.nih.gov/pubmed/37698279
http://dx.doi.org/10.1021/acsinfecdis.3c00324
_version_ 1785121915343470592
author Quintana, Isabella de la Luz
Paul, Ankita
Chowdhury, Aniqa
Moulton, Karen D.
Kulkarni, Suvarn S.
Dube, Danielle H.
author_facet Quintana, Isabella de la Luz
Paul, Ankita
Chowdhury, Aniqa
Moulton, Karen D.
Kulkarni, Suvarn S.
Dube, Danielle H.
author_sort Quintana, Isabella de la Luz
collection PubMed
description [Image: see text] Glycans that coat the surface of bacteria are compelling antibiotic targets because they contain distinct monosaccharides that are linked to pathogenesis and are absent in human cells. Disrupting glycan biosynthesis presents a path to inhibiting the ability of a bacterium to infect the host. We previously demonstrated that O-glycosides act as metabolic inhibitors and disrupt bacterial glycan biosynthesis. Inspired by a recent study which showed that thioglycosides (S-glycosides) are 10 times more effective than O-glycosides at inhibiting glycan biosynthesis in mammalian cells, we crafted a panel of S-glycosides based on rare bacterial monosaccharides. The novel thioglycosides altered glycan biosynthesis and fitness in pathogenic bacteria but had no notable effect on glycosylation or growth in beneficial bacteria or mammalian cells. In contrast to findings in mammalian cells, S-glycosides and O-glycosides exhibited comparable potency in bacteria. However, S-glycosides exhibited enhanced selectivity relative to O-glycosides. These novel metabolic inhibitors will allow selective perturbation of the bacterial glycocalyx for functional studies and set the stage to expand our antibiotic arsenal.
format Online
Article
Text
id pubmed-10580310
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-105803102023-10-18 Thioglycosides Act as Metabolic Inhibitors of Bacterial Glycan Biosynthesis Quintana, Isabella de la Luz Paul, Ankita Chowdhury, Aniqa Moulton, Karen D. Kulkarni, Suvarn S. Dube, Danielle H. ACS Infect Dis [Image: see text] Glycans that coat the surface of bacteria are compelling antibiotic targets because they contain distinct monosaccharides that are linked to pathogenesis and are absent in human cells. Disrupting glycan biosynthesis presents a path to inhibiting the ability of a bacterium to infect the host. We previously demonstrated that O-glycosides act as metabolic inhibitors and disrupt bacterial glycan biosynthesis. Inspired by a recent study which showed that thioglycosides (S-glycosides) are 10 times more effective than O-glycosides at inhibiting glycan biosynthesis in mammalian cells, we crafted a panel of S-glycosides based on rare bacterial monosaccharides. The novel thioglycosides altered glycan biosynthesis and fitness in pathogenic bacteria but had no notable effect on glycosylation or growth in beneficial bacteria or mammalian cells. In contrast to findings in mammalian cells, S-glycosides and O-glycosides exhibited comparable potency in bacteria. However, S-glycosides exhibited enhanced selectivity relative to O-glycosides. These novel metabolic inhibitors will allow selective perturbation of the bacterial glycocalyx for functional studies and set the stage to expand our antibiotic arsenal. American Chemical Society 2023-09-12 /pmc/articles/PMC10580310/ /pubmed/37698279 http://dx.doi.org/10.1021/acsinfecdis.3c00324 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Quintana, Isabella de la Luz
Paul, Ankita
Chowdhury, Aniqa
Moulton, Karen D.
Kulkarni, Suvarn S.
Dube, Danielle H.
Thioglycosides Act as Metabolic Inhibitors of Bacterial Glycan Biosynthesis
title Thioglycosides Act as Metabolic Inhibitors of Bacterial Glycan Biosynthesis
title_full Thioglycosides Act as Metabolic Inhibitors of Bacterial Glycan Biosynthesis
title_fullStr Thioglycosides Act as Metabolic Inhibitors of Bacterial Glycan Biosynthesis
title_full_unstemmed Thioglycosides Act as Metabolic Inhibitors of Bacterial Glycan Biosynthesis
title_short Thioglycosides Act as Metabolic Inhibitors of Bacterial Glycan Biosynthesis
title_sort thioglycosides act as metabolic inhibitors of bacterial glycan biosynthesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580310/
https://www.ncbi.nlm.nih.gov/pubmed/37698279
http://dx.doi.org/10.1021/acsinfecdis.3c00324
work_keys_str_mv AT quintanaisabelladelaluz thioglycosidesactasmetabolicinhibitorsofbacterialglycanbiosynthesis
AT paulankita thioglycosidesactasmetabolicinhibitorsofbacterialglycanbiosynthesis
AT chowdhuryaniqa thioglycosidesactasmetabolicinhibitorsofbacterialglycanbiosynthesis
AT moultonkarend thioglycosidesactasmetabolicinhibitorsofbacterialglycanbiosynthesis
AT kulkarnisuvarns thioglycosidesactasmetabolicinhibitorsofbacterialglycanbiosynthesis
AT dubedanielleh thioglycosidesactasmetabolicinhibitorsofbacterialglycanbiosynthesis